Evidence map›Paper›PMID 32652045›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2020

Adiponectin Stimulates Exosome Release to Enhance Mesenchymal Stem-Cell-Driven Therapy of Heart Failure in Mice.

Yuto Nakamura, Shunbun Kita, Yoshimitsu Tanaka, Shiro Fukuda, Yoshinari Obata, Tomonori Okita, Hiroyuki Nishida, Yuki Takahashi, Yusuke Kawachi, Yuri Tsugawa-Shimizu and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 2 syntheses or guidelines pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. T-cadherin, a major adiponectin binding partner, suppresses ERK signaling in metabolic tissues.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Yuto NakamuraDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Shunbun KitaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Adipose Management, Graduate School of Medicine, Osaka University, Osaka, Japan. Electronic address: shunkita@endmet.med.osaka-u.ac.jp.
Yoshimitsu TanakaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Shiro FukudaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yoshinari ObataDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Tomonori OkitaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hiroyuki NishidaROHTO Pharmaceutical Co., Ltd. Osaka, Japan; Department of Advanced Stem Cell Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuki TakahashiDepartment of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Yusuke KawachiDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuri Tsugawa-ShimizuDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yuya FujishimaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hitoshi NishizawaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yoshinobu TakakuraDepartment of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Shigeru MiyagawaDepartment of Cardiovascular Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Yoshiki SawaDepartment of Cardiovascular Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan; Medical Center for Translational Research, Osaka University Hospital, Osaka, Japan.
Norikazu MaedaDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, Osaka, Japan.
Iichiro ShimomuraDepartment of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
The University of Osaka · JPKyoto University · JPOsaka City University · JPOsaka University Hospital · JPRohto Pharmaceutical (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem/stromal cells (MSCs) are cultured adult stem cells that originally reside in virtually all tissues, and the gain of MSCs by transplantation has become the leading form of cell therapy in various diseases. However, there is limited knowledge on the alteration of its efficacy by factors in recipients. Here, we report that the cardioprotective properties of intravenously injected MSCs in a mouse model of pressure-overload heart failure largely depend on circulating adiponectin, an adipocyte-secreted factor. The injected MSCs exert their function through exosomes, extracellular vesicles of endosome origin. Adiponectin stimulated exosome biogenesis and secretion through binding to T-cadherin, a unique glycosylphosphatidylinositol-anchored cadherin, on MSCs. A pharmacological or adenovirus-mediated genetic increase in plasma adiponectin enhanced the therapeutic efficacy of MSCs. Our findings provide novel insights into the importance of adiponectin in mesenchymal-progenitor-mediated organ protections.

Indexed as

Mesenchymal Stem Cell TransplantationAdiponectinAnimalsCadherinsCells, CulturedDisease Models, AnimalDisease SusceptibilityExosomesExtracellular VesiclesHeart FailureHumansMesenchymal Stem CellsMiceAdiponectinCadherinsH-cadherinadiponectinexosomeextracellular vesicleheart failuremesenchymal stem/stromal cellMSCTAC modelT-cadherin

Identifiers

PMID32652045
PMCPMC7351027
OpenAlexW3041596122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.